Written Testimony in Support of Senate Bill 121 before the Ohio Senate Insurance and Financial Institutions Committee Senator Jay Hottinger, Chairman

By Camille Grubbs, Hologic

October 3, 2017

Chairman Hottinger, Vice-Chairman Hackett, Ranking Member Brown and members of the Senate Insurance and Financial Institutions Committee, my name is Camille Grubbs and I am submitting written testimony in support of SB 121 on behalf of Hologic. Thank you for the opportunity to testify in support of Senate Bill 121, sponsored by Senator John Eklund.

Hologic is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. Hologic was the first manufacturer to bring breast tomosynthesis (the Genius™ 3D Mammography™ exam) to the market, enabling greater accuracy in detection and a reduced chance that a patient is called back for additional screenings.[1]

Clinical data with **over 250 peer-reviewed publications**, representing over **850,000 patients**, continues to deliver consistent outcomes when implementing breast tomosynthesis. As a result of these positive clinical outcomes, adoption of this technology around the US has been overwhelming, with 145 breast centers in Ohio.

Here are **proven facts** about DBT, some of which may lead to a reduction in healthcare costs:

- **Reduces callbacks** up to 40% compared to 2D alone [2-3]
- **Detects more invasive breast cancer** compared to 2D mammography alone[2, 4]
- Over **11m patients have been screened** nationwide with DBT, since 2011
- **85% of all Women ages 40-74 in the US have access** through coverage and reimbursement for DBT through
- **Multiple society support the use of DBT including** National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR) and American College of Obstetrics & Gynecology (ACOG)

---

[1] McDonald ES, Oustimov A, Weinstein SP, et al. *Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography.* JAMA Oncol. 2016.

2. Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.

3. Bernardi D, Macaskill P, Pellegrini M et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.

4. Results of studies done on a Hologic 3D Mammography System

MISC-04842

The Genius™3D Mammography™ exam (a.k.a.Genius™ exam) is acquired on the Hologic® 3D Mammography™ system and consists of a 2D and 3D™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™ image set.The Genius™ exam is only available on the Hologic® 3D Mammography™ system.

- **NCQA** released (July 2017) updated **HEDIS** guidelines, adding DBT to the list of acceptable tests

Senate Bill 121 would make it clear that tomosynthesis is part of screening mammography and provide certainty to our patients that they have coverage when tomosynthesis is used to better detect any potential abnormalities.

Thank you again for the opportunity to testify in support of SB 121. I urge your favorable vote on this important bill.

Sincerely,

Camille Grubbs
Hologic
Senior Manager, Health Policy and Reimbursement
312.882.6412
camillegrubbs@hologic.com